These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 15047538)

  • 1. Potent synergistic in vitro interaction between nonantimicrobial membrane-active compounds and itraconazole against clinical isolates of Aspergillus fumigatus resistant to itraconazole.
    Afeltra J; Vitale RG; Mouton JW; Verweij PE
    Antimicrob Agents Chemother; 2004 Apr; 48(4):1335-43. PubMed ID: 15047538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of fractional inhibitory concentration index with response surface modeling for characterization of in vitro interaction of antifungals against itraconazole-susceptible and -resistant Aspergillus fumigatus isolates.
    Te Dorsthorst DT; Verweij PE; Meis JF; Punt NC; Mouton JW
    Antimicrob Agents Chemother; 2002 Mar; 46(3):702-7. PubMed ID: 11850251
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The concentration-dependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions.
    Meletiadis J; te Dorsthorst DT; Verweij PE
    Int J Antimicrob Agents; 2006 Nov; 28(5):439-49. PubMed ID: 17055706
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro susceptibilities of Aspergillus species to voriconazole, itraconazole, and amphotericin B.
    Abraham OC; Manavathu EK; Cutright JL; Chandrasekar PH
    Diagn Microbiol Infect Dis; 1999 Jan; 33(1):7-11. PubMed ID: 9990469
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro interactions between amphotericin B, itraconazole, and flucytosine against 21 clinical Aspergillus isolates determined by two drug interaction models.
    Te Dorsthorst DT; Verweij PE; Meis JF; Punt NC; Mouton JW
    Antimicrob Agents Chemother; 2004 Jun; 48(6):2007-13. PubMed ID: 15155192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of SCH-56592 in a temporarily neutropenic murine model of invasive aspergillosis with an itraconazole-susceptible and an itraconazole-resistant isolate of Aspergillus fumigatus.
    Oakley KL; Morrissey G; Denning DW
    Antimicrob Agents Chemother; 1997 Jul; 41(7):1504-7. PubMed ID: 9210674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates.
    Meletiadis J; Mouton JW; Meis JF; Verweij PE
    Antimicrob Agents Chemother; 2003 Jan; 47(1):106-17. PubMed ID: 12499177
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison Between Etest and Broth Microdilution Methods for Testing Itraconazole-Resistant Aspergillus fumigatus Susceptibility to Antifungal Combinations.
    Denardi LB; Keller JT; de Azevedo MI; Oliveira V; Piasentin FB; Severo CB; Santurio JM; Alves SH
    Mycopathologia; 2018 Apr; 183(2):359-370. PubMed ID: 28994001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aspergillus species collected from environmental air samples in Portugal-molecular identification, antifungal susceptibility and sequencing of cyp51A gene on A. fumigatus sensu stricto itraconazole resistant.
    Monteiro C; Pinheiro D; Maia M; Faria MA; Lameiras C; Pinto E
    J Appl Microbiol; 2019 Apr; 126(4):1140-1148. PubMed ID: 30735287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism.
    Snelders E; van der Lee HA; Kuijpers J; Rijs AJ; Varga J; Samson RA; Mellado E; Donders AR; Melchers WJ; Verweij PE
    PLoS Med; 2008 Nov; 5(11):e219. PubMed ID: 18998768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of in vitro antifungal activities of amphotericin B lipid complex with itraconazole against 708 clinical yeast isolates and opportunistic moulds determined by National Committee for Clinical Laboratory Standards methods M27-A and M38-P.
    Carrillo-Muñoz AJ; Ruesga M; Brio S; del Valle O; Rodriguez V; Santos P; Hernández-Molina JM; Cantón E; Pemán J; Guarro J; Quindós G
    Chemotherapy; 2002 Dec; 48(5):224-31. PubMed ID: 12476038
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serotonin (5-HT) enhances the activity of amphotericin B against Aspergillus fumigatus in vitro.
    Heller I; Leitner S; Dierich MP; Lass-Flörl C
    Int J Antimicrob Agents; 2004 Oct; 24(4):401-4. PubMed ID: 15380269
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vitro susceptibility testing of ciclopirox, terbinafine, ketoconazole and itraconazole against dermatophytes and nondermatophytes, and in vitro evaluation of combination antifungal activity.
    Gupta AK; Kohli Y
    Br J Dermatol; 2003 Aug; 149(2):296-305. PubMed ID: 12932235
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modified release itraconazole amorphous solid dispersion to treat Aspergillus fumigatus: importance of the animal model selection.
    Maincent JP; Najvar LK; Kirkpatrick WR; Huang S; Patterson TF; Wiederhold NP; Peters JI; Williams RO
    Drug Dev Ind Pharm; 2017 Feb; 43(2):264-274. PubMed ID: 27645428
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined activity in vitro of caspofungin, amphotericin B, and azole agents against itraconazole-resistant clinical isolates of Aspergillus fumigatus.
    Cuenca-Estrella M; Gomez-Lopez A; Garcia-Effron G; Alcazar-Fuoli L; Mellado E; Buitrago MJ; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1232-5. PubMed ID: 15728937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of the MICs Obtained by Gradient Concentration Strip and EUCAST Methods for Four Azole Drugs and Amphotericin B against Azole-Susceptible and -Resistant
    Dellière S; Verdurme L; Bigot J; Dannaoui E; Senghor Y; Botterel F; Fekkar A; Bougnoux ME; Hennequin C; Guitard J
    Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844011
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nationwide survey of in vitro activities of itraconazole and voriconazole against clinical Aspergillus fumigatus isolates cultured between 1945 and 1998.
    Verweij PE; Te Dorsthorst DT; Rijs AJ; De Vries-Hospers HG; Meis JF
    J Clin Microbiol; 2002 Jul; 40(7):2648-50. PubMed ID: 12089298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. First determination of azole resistance in Aspergillus fumigatus strains carrying the TR34/L98H mutations in Turkey.
    Özmerdiven GE; Ak S; Ener B; Ağca H; Cilo BD; Tunca B; Akalın H
    J Infect Chemother; 2015 Aug; 21(8):581-6. PubMed ID: 26048062
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synergistic interaction of terbinafine with triazoles or amphotericin B against Aspergillus species.
    Ryder NS; Leitner I
    Med Mycol; 2001 Feb; 39(1):91-5. PubMed ID: 11270414
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of voriconazole in a patient with aspergilloma caused by an itraconazole-resistant strain of Aspergillus fumigatus.
    Dannaoui E; Garcia-Hermoso D; Naccache JM; Meneau I; Sanglard D; Bouges-Michel C; Valeyre D; Lortholary O
    J Med Microbiol; 2006 Oct; 55(Pt 10):1457-1459. PubMed ID: 17005798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.